Editorial
Copyright ©The Author(s) 2024.
World J Gastroenterol. Mar 21, 2024; 30(11): 1480-1487
Published online Mar 21, 2024. doi: 10.3748/wjg.v30.i11.1480
Figure 1
Figure 1 Interplay between coronavirus disease 2019 and metabolic dysfunction-associated fatty liver disease. Metabolic dysfunction-associated fatty liver disease (MAFLD) can increase the susceptibility and severity of coronavirus disease 2019 (COVID-19). Conversely, COVID-19 can promote the progression of preexisting MAFLD. MAFLD: Metabolic dysfunction-associated fatty liver disease; ACE2: Angiotensin-converting enzyme 2; TMPRSS2: Trans-membrane protease serine 2; SIRS: Systematic inflammatory response syndrome; HIFs: Hypoxia-induced factors; DILI: Drug-induced liver injury; COVID-19: Coronavirus disease 2019.